Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315027 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
A Phase 1 study of MSA, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02315027 is a Phase 1 study of MSA that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02315027, a Phase 1 study of MSA, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Mesenchymal Stem Cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-10 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315027
The ClinicalTrials.gov registry entry for NCT02315027 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MSA appearing as the primary indexed condition, and to 1 intervention - of which Autologous Mesenchymal Stem Cells is the first listed.
NCT02315027 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02315027 about?
NCT02315027 is a clinical study titled "Mesenchymal Stem Cell Therapy in Multiple System Atrophy". The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.
What is the current status of trial NCT02315027?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-10. Estimated completion is 2026-03.
What conditions does trial NCT02315027 study?
This clinical trial studies the following conditions: MSA.
What interventions are being tested in trial NCT02315027?
The interventions under investigation include: Autologous Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02315027?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02315027 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MSA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.